MNG642
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.474
- UV_RESPONSE_DN+0.406
- TGF_BETA_SIGNALING+0.363
- MYC_TARGETS_V1+0.283
- ANDROGEN_RESPONSE+0.271
- MITOTIC_SPINDLE+0.271
- UNFOLDED_PROTEIN_RESPONSE+0.260
- G2M_CHECKPOINT+0.229
- E2F_TARGETS+0.213
- INTERFERON_GAMMA_RESPONSE+0.197
Top 10 suppressed
- ANGIOGENESIS-0.401
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.395
- CHOLESTEROL_HOMEOSTASIS-0.342
- ESTROGEN_RESPONSE_LATE-0.339
- MYOGENESIS-0.327
- KRAS_SIGNALING_DN-0.292
- COAGULATION-0.289
- APICAL_SURFACE-0.282
- OXIDATIVE_PHOSPHORYLATION-0.278
- APICAL_JUNCTION-0.241
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG724 | — | — | 0.922 |
| 2 | MNG997 | — | — | 0.804 |
| 3 | MDT-AP-3199 | Med | Medulloblastoma | 0.788 |
| 4 | MNG59 | — | — | 0.776 |
| 5 | R144 | — | — | 0.774 |
| 6 | MNG1220 | — | — | 0.773 |
| 7 | SRR650203 | — | — | 0.764 |
| 8 | GSM6454750 | — | D | 0.756 |
| 9 | MNG573 | — | — | 0.755 |
| 10 | MNG611 | — | — | 0.754 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.474 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.406 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.363 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.283 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.271 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.271 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.260 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.229 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.213 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.197 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.175 | Inavolisib | — uncovered |
| PEROXISOME | 0.174 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.163 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.155 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.114 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.072 | Temsirolimus | — uncovered |